Spearhead Capital Advisors’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,365
Closed -$222K 149
2022
Q2
$222K Sell
1,365
-22
-2% -$3.48K 0.03% 161
2022
Q1
$261K Sell
1,387
-715
-34% -$136K 0.03% 159
2021
Q4
$557K Buy
2,102
+8
+0.4% +$2.15K 0.07% 92
2021
Q3
$605K Sell
2,094
-9
-0.4% -$2.31K 0.08% 81
2021
Q2
$420K Buy
2,103
+234
+13% +$45.4K 0.06% 134
2021
Q1
$363K Sell
1,869
-499
-21% -$102K 0.05% 113
2020
Q4
$454K Sell
2,368
-469
-17% -$85.3K 0.07% 107
2020
Q3
$419K Buy
2,837
+655
+30% +$93.6K 0.08% 93
2020
Q2
$270K Buy
+2,182
New +$257K 0.06% 120

Other funds holding RGEN

Spearhead Capital Advisors's RGEN Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Repligen (RGEN) in Q3 2022, closing a stake of 1,365 shares — an estimated $222K sold.

Spearhead Capital Advisors first reported a position in RGEN in Q2 2020 and held it in 9 quarters. The position peaked at $605K in Q3 2021. 434 funds tracked by Wall St. Rank hold RGEN as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Repligen position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 1,365 Repligen shares in Q3 2022, an estimated $222K.
  • Spearhead Capital Advisors first reported a position in Repligen in Q2 2020 and held it in 9 quarters.
  • Spearhead Capital Advisors's Repligen position peaked at $605K in Q3 2021.
  • 434 funds tracked by Wall St. Rank held Repligen as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.